Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Beone Medicines Ltd. (ONC) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Beone Medicines Ltd.. Table 2 shows the detailed insider transactions. This company's CIK number is 1651308.
Total stock buying since 2016: $948,079,384.
Total stock sales since 2016: $6,175,553,111.
Total stock option exercises since 2016: $70,516,106.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 1,456,704 | $375,332,844 | 2,336,986 | $47,980,297 |
| 2024 | 0 | $0 | 19,117,537 | $3,815,653,609 | 1,380,221 | $1,171,436 |
| 2023 | 0 | $0 | 4,260,548 | $801,862,198 | 67,635 | $8,792 |
| 2022 | 0 | $0 | 120,062 | $21,381,114 | 1,233,947 | $3,566,106 |
| 2021 | 165,529 | $50,000,020 | 1,552,008 | $463,535,154 | 105,003 | $4,906,771 |
| 2020 | 0 | $0 | 2,361,950 | $530,233,023 | 1,559,200 | $7,421,383 |
| 2019 | 0 | $0 | 295,150 | $45,912,136 | 133,625 | $3,059,078 |
| 2018 | 7,794,298 | $827,922,798 | 272,012 | $39,141,595 | 108,000 | $2,328,468 |
| 2017 | 176,056 | $12,499,976 | 1,180,611 | $73,572,490 | 2,500 | $73,775 |
| 2016 | 11,085,495 | $57,656,590 | 286,057 | $8,928,948 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 0 | $0 | 122 | $39,864 | 0 | $0 |
| 2025-08 | 0 | $0 | 101,997 | $30,978,732 | 98,024 | $15,968,093 |
| 2025-07 | 0 | $0 | 33,722 | $8,843,992 | 0 | $0 |
| 2025-06 | 0 | $0 | 68,011 | $17,798,172 | 41,760 | $271,440 |
| 2025-05 | 0 | $0 | 41,760 | $9,356,703 | 41,760 | $271,440 |
| 2025-04 | 0 | $0 | 93,681 | $24,818,293 | 93,681 | $7,913,951 |
| 2025-03 | 0 | $0 | 241,736 | $61,701,140 | 1,926,320 | $14,204,096 |
| 2025-02 | 0 | $0 | 833,915 | $214,386,722 | 93,681 | $9,079,837 |
| 2025-01 | 0 | $0 | 41,760 | $7,409,226 | 41,760 | $271,440 |
| 2024-12 | 0 | $0 | 18,921,277 | $3,780,963,570 | 1,341,760 | $921,440 |
| 2024-11 | 0 | $0 | 48,351 | $9,170,347 | 38,461 | $249,996 |
| 2024-10 | 0 | $0 | 16,175 | $3,765,070 | 0 | $0 |
| 2024-09 | 0 | $0 | 16,895 | $3,469,790 | 0 | $0 |
| 2024-06 | 0 | $0 | 14,442 | $2,284,686 | 0 | $0 |
| 2024-04 | 0 | $0 | 50,000 | $7,487,441 | 0 | $0 |
| 2024-03 | 0 | $0 | 50,000 | $8,446,375 | 0 | $0 |
| 2024-02 | 0 | $0 | 397 | $66,330 | 0 | $0 |
| 2023-07 | 0 | $0 | 1,263 | $255,806 | 0 | $0 |
| 2023-06 | 0 | $0 | 4,163,916 | $779,418,411 | 0 | $0 |
| 2023-05 | 0 | $0 | 7,000 | $1,776,040 | 0 | $0 |
| 2023-03 | 0 | $0 | 67,978 | $15,340,374 | 67,635 | $8,792 |
| 2023-01 | 0 | $0 | 20,391 | $5,071,567 | 0 | $0 |
| 2022-12 | 0 | $0 | 9,609 | $2,158,196 | 0 | $0 |
| 2022-11 | 0 | $0 | 29,928 | $6,190,726 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | Ball Titus B. (Principal Accounting Officer) | Sale | 122 | 326.76 | 39,864 |
| 2025-08-14 | Wu Xiaobin (President and COO) | Sale | 39,936 | 304.70 | 12,168,579 |
| 2025-08-14 | Wu Xiaobin (President and COO) | Option Ex | 39,936 | 157.35 | 6,284,129 |
| 2025-08-13 | Lee Chan Henry (SVP, General Counsel) | Sale | 11,013 | 300.40 | 3,308,261 |
| 2025-08-13 | Lee Chan Henry (SVP, General Counsel) | Option Ex | 8,230 | 176.75 | 1,454,652 |
| 2025-08-13 | Wu Xiaobin (President and COO) | Sale | 49,858 | 303.99 | 15,156,233 |
| 2025-08-13 | Wu Xiaobin (President and COO) | Option Ex | 49,858 | 165.06 | 8,229,312 |
| 2025-08-01 | Rosenberg Aaron (Chief Financial Officer) | Sale | 1,190 | 290.47 | 345,659 |
| 2025-07-30 | Lee Chan Henry (SVP, General Counsel) | Sale | 920 | 304.60 | 280,232 |
| 2025-07-30 | Wang Lai (Global Head of R&D) | Sale | 259 | 305.00 | 78,995 |
| 2025-07-29 | Wang Lai (Global Head of R&D) | Sale | 4,041 | 303.03 | 1,224,540 |
| 2025-07-18 | Wang Lai (Global Head of R&D) | Sale | 700 | 300.00 | 210,000 |
| 2025-07-09 | Oyler John (Chief Executive Officer) | Sale | 27,802 | 253.59 | 7,050,225 |
| 2025-06-24 | Wang Xiaodong (Director) | Sale | 2,007 | 265.81 | 533,474 |
| 2025-06-23 | Wang Lai (Global Head of R&D) | Sale | 1,028 | 260.00 | 267,280 |
| 2025-06-23 | Wu Xiaobin (President and COO) | Sale | 1,363 | 260.00 | 354,380 |
| 2025-06-23 | Oyler John (Chief Executive Officer) | Sale | 3,174 | 262.24 | 832,337 |
| 2025-06-17 | Wang Lai (Global Head of R&D) | Sale | 470 | 251.37 | 118,141 |
| 2025-06-17 | Wu Xiaobin (President and COO) | Sale | 630 | 250.87 | 158,047 |
| 2025-06-17 | Oyler John (Chief Executive Officer) | Sale | 1,460 | 256.49 | 374,473 |
| 2025-06-16 | Lee Chan Henry (SVP, General Counsel) | Sale | 422 | 266.50 | 112,463 |
| 2025-06-16 | Wang Lai (Global Head of R&D) | Sale | 1,177 | 266.40 | 313,557 |
| 2025-06-16 | Wu Xiaobin (President and COO) | Sale | 1,543 | 265.85 | 410,198 |
| 2025-06-16 | Oyler John (Chief Executive Officer) | Sale | 3,680 | 266.05 | 979,045 |
| 2025-06-11 | Ball Titus B. (Principal Accounting Officer) | Sale | 134 | 258.36 | 34,620 |
| 2025-06-10 | Wang Xiaodong (Director) | Sale | 41,760 | 263.10 | 10,987,139 |
| 2025-06-10 | Wang Xiaodong (Director) | Option Ex | 41,760 | 6.50 | 271,440 |
| 2025-06-06 | Lee Chan Henry (SVP, General Counsel) | Sale | 700 | 256.29 | 179,401 |
| 2025-06-06 | Wang Lai (Global Head of R&D) | Sale | 1,402 | 252.77 | 354,386 |
| 2025-06-06 | Wu Xiaobin (President and COO) | Sale | 1,934 | 253.43 | 490,137 |
| 2025-06-06 | Oyler John (Chief Executive Officer) | Sale | 5,127 | 253.38 | 1,299,094 |
| 2025-05-13 | Wang Xiaodong (Director) | Sale | 41,760 | 224.06 | 9,356,703 |
| 2025-05-13 | Wang Xiaodong (Director) | Option Ex | 41,760 | 6.50 | 271,440 |
| 2025-04-14 | Wang Xiaodong (Director) | Sale | 41,760 | 243.52 | 10,169,562 |
| 2025-04-14 | Wang Xiaodong (Director) | Option Ex | 41,760 | 6.50 | 271,440 |
| 2025-04-01 | Wu Xiaobin (President, COO & GM China) | Sale | 51,921 | 282.13 | 14,648,731 |
| 2025-04-01 | Wu Xiaobin (President, COO & GM China) | Option Ex | 51,921 | 147.19 | 7,642,511 |
| 2025-03-18 | Wang Xiaodong (Director) | Sale | 41,760 | 261.12 | 10,904,371 |
| 2025-03-18 | Wang Xiaodong (Director) | Option Ex | 41,760 | 6.50 | 271,440 |
| 2025-03-10 | Oyler John (Chief Executive Officer) | Sale | 41,210 | 242.91 | 10,010,238 |
| 2025-03-10 | Oyler John (Chief Executive Officer) | Option Ex | 539,032 | 3.50 | 1,886,612 |
| 2025-03-07 | Oyler John (Chief Executive Officer) | Sale | 58,590 | 250.34 | 14,667,303 |
| 2025-03-07 | Oyler John (Chief Executive Officer) | Option Ex | 767,337 | 3.50 | 2,685,679 |
| 2025-03-06 | Oyler John (Chief Executive Officer) | Sale | 40,109 | 260.48 | 10,447,712 |
| 2025-03-06 | Oyler John (Chief Executive Officer) | Option Ex | 526,270 | 3.50 | 1,841,945 |
| 2025-03-05 | Wu Xiaobin (President, COO & GM China) | Sale | 51,921 | 261.88 | 13,596,967 |
| 2025-03-05 | Wu Xiaobin (President, COO & GM China) | Option Ex | 51,921 | 144.81 | 7,518,420 |
| 2025-03-04 | Wang Xiaodong (Director) | Sale | 8,146 | 254.67 | 2,074,549 |
| 2025-02-28 | Baker Julian | Sale | 732,827 | 260.00 | 190,535,020 |
| 2025-02-27 | Lee Chan Henry (SVP, General Counsel) | Sale | 1,205 | 275.00 | 331,375 |
| 2025-02-21 | Lee Chan Henry (SVP, General Counsel) | Sale | 1,202 | 258.58 | 310,817 |
| 2025-02-21 | Wang Lai (Global Head of R&D) | Sale | 5,000 | 257.41 | 1,287,045 |
| 2025-02-20 | Wu Xiaobin (President, COO & GM China) | Sale | 21,267 | 240.07 | 5,105,504 |
| 2025-02-20 | Wu Xiaobin (President, COO & GM China) | Option Ex | 21,267 | 169.65 | 3,607,946 |
| 2025-02-18 | Wu Xiaobin (President, COO & GM China) | Sale | 30,654 | 241.22 | 7,394,235 |
| 2025-02-18 | Wu Xiaobin (President, COO & GM China) | Option Ex | 30,654 | 169.65 | 5,200,451 |
| 2025-02-04 | Wang Xiaodong (Director) | Sale | 41,760 | 225.64 | 9,422,726 |
| 2025-02-04 | Wang Xiaodong (Director) | Option Ex | 41,760 | 6.50 | 271,440 |
| 2025-01-07 | Wang Xiaodong (Director) | Sale | 41,760 | 177.42 | 7,409,226 |
| 2025-01-07 | Wang Xiaodong (Director) | Option Ex | 41,760 | 6.50 | 271,440 |
| 2024-12-14 | Oyler John (Chief Executive Officer) | Option Ex | 1,300,000 | .50 | 650,000 |
| 2024-12-10 | Wang Xiaodong (Director) | Sale | 41,760 | 189.29 | 7,904,708 |
| 2024-12-10 | Wang Xiaodong (Director) | Option Ex | 41,760 | 6.50 | 271,440 |
| 2024-12-09 | Baker Julian | Sale | 1,037,017 | 197.26 | 204,558,862 |
| 2024-12-02 | Hillhouse Investment Management, Ltd. | Sale | 17,842,500 | 200.00 | 3,568,500,000 |
| 2024-11-26 | Wang Xiaodong (Director) | Sale | 48,351 | 189.66 | 9,170,347 |
| 2024-11-26 | Wang Xiaodong (Director) | Option Ex | 38,461 | 6.50 | 249,996 |
| 2024-10-08 | Oyler John (Chief Executive Officer) | Sale | 16,175 | 232.77 | 3,765,070 |
| 2024-09-30 | Lee Chan Henry (SVP, General Counsel) | Sale | 1,202 | 237.10 | 284,994 |
| 2024-09-27 | Wang Lai (Global Head of R&D) | Sale | 5,000 | 220.35 | 1,101,775 |
| 2024-09-19 | Wu Xiaobin (President, COO & GM China) | Sale | 4,500 | 200.14 | 900,616 |
| 2024-09-17 | Wu Xiaobin (President, COO & GM China) | Sale | 500 | 200.00 | 100,000 |
| 2024-09-03 | Wu Xiaobin (President, COO & GM China) | Sale | 5,556 | 190.13 | 1,056,384 |
| 2024-09-03 | Ball Titus B. (Principal Accounting Officer) | Sale | 137 | 189.94 | 26,021 |
| 2024-06-24 | Wang Julia Aijun (Chief Financial Officer) | Sale | 899 | 155.66 | 139,938 |
| 2024-06-24 | Wang Lai (Global Head of R&D) | Sale | 1,064 | 160.45 | 170,718 |
| 2024-06-24 | Wu Xiaobin (President, COO & GM China) | Sale | 1,459 | 160.39 | 234,013 |
| 2024-06-24 | Oyler John (Chief Executive Officer) | Sale | 2,789 | 159.81 | 445,701 |
| 2024-06-18 | Wang Lai (Global Head of R&D) | Sale | 841 | 153.75 | 129,304 |
| 2024-06-18 | Wu Xiaobin (President, COO & GM China) | Sale | 2,627 | 154.95 | 407,043 |
| 2024-06-17 | Lee Chan Henry (SVP, General Counsel) | Sale | 439 | 159.20 | 69,890 |
| 2024-06-17 | Wang Julia Aijun (Chief Financial Officer) | Sale | 916 | 158.89 | 145,543 |
| 2024-06-17 | Wang Lai (Global Head of R&D) | Sale | 1,500 | 159.21 | 238,808 |
| 2024-06-17 | Wu Xiaobin (President, COO & GM China) | Sale | 627 | 159.00 | 99,691 |
| 2024-06-17 | Oyler John (Chief Executive Officer) | Sale | 1,281 | 159.28 | 204,037 |
| 2024-04-11 | Oyler John (Chief Executive Officer) | Sale | 12,084 | 146.88 | 1,774,922 |
| 2024-04-10 | Oyler John (Chief Executive Officer) | Sale | 26,716 | 149.55 | 3,995,324 |
| 2024-04-09 | Oyler John (Chief Executive Officer) | Sale | 11,200 | 153.32 | 1,717,195 |
| 2024-03-13 | Oyler John (Chief Executive Officer) | Sale | 12,332 | 179.91 | 2,218,687 |
| 2024-03-12 | Oyler John (Chief Executive Officer) | Sale | 37,668 | 165.33 | 6,227,688 |
| 2024-02-29 | Wang Julia Aijun (Chief Financial Officer) | Sale | 397 | 167.08 | 66,330 |
| 2023-07-31 | Lee Chan Henry (SVP, General Counsel) | Sale | 791 | 216.26 | 171,059 |
| 2023-07-03 | Wang Julia Aijun (Chief Financial Officer) | Sale | 472 | 179.55 | 84,747 |
| 2023-06-26 | Wang Lai (Global Head of R&D) | Sale | 1,108 | 182.53 | 202,245 |
| 2023-06-26 | Wu Xiaobin (President, COO & GM China) | Sale | 1,495 | 182.37 | 272,635 |
| 2023-06-23 | Wang Julia Aijun (Chief Financial Officer) | Sale | 840 | 182.85 | 153,594 |
| 2023-06-23 | Sanders Corazon (corsee) D. | Sale | 578 | 181.70 | 105,020 |
| 2023-06-20 | Wang Lai (Global Head of R&D) | Sale | 1,325 | 192.42 | 254,955 |
| 2023-06-14 | Hillhouse Investment Management, Ltd. | Sale | 273,728 | 207.72 | 56,857,958 |
| 2023-06-13 | Hillhouse Investment Management, Ltd. | Sale | 924,400 | 169.94 | 157,095,309 |
| 2023-06-12 | Hillhouse Investment Management, Ltd. | Sale | 1,250,212 | 172.37 | 215,501,542 |
| 2023-06-09 | Hillhouse Investment Management, Ltd. | Sale | 542,652 | 173.69 | 94,250,512 |
| 2023-06-08 | Hillhouse Investment Management, Ltd. | Sale | 1,163,825 | 218.14 | 253,881,440 |
| 2023-06-07 | Wang Lai (Global Head of R&D) | Sale | 462 | 224.67 | 103,799 |
| 2023-06-07 | Wu Xiaobin (President, COO & GM China) | Sale | 3,291 | 224.67 | 739,402 |
| 2023-05-08 | Wu Xiaobin (President, COO & GM China) | Sale | 7,000 | 253.72 | 1,776,040 |
| 2023-03-08 | Wang Xiaodong | Sale | 67,635 | 225.59 | 15,257,982 |
| 2023-03-08 | Wang Xiaodong | Option Ex | 67,635 | .13 | 8,792 |
| 2023-03-01 | Wang Julia Aijun (Chief Financial Officer) | Sale | 343 | 240.21 | 82,392 |
| 2023-01-10 | Oyler John (Chief Executive Officer) | Sale | 20,391 | 248.72 | 5,071,567 |
| 2022-12-29 | Oyler John (Chief Executive Officer) | Sale | 5,150 | 224.78 | 1,157,596 |
| 2022-12-28 | Oyler John (Chief Executive Officer) | Sale | 1,100 | 224.72 | 247,197 |
| 2022-12-27 | Oyler John (Chief Executive Officer) | Sale | 3,359 | 224.29 | 753,403 |
| 2022-11-15 | Oyler John (Chief Executive Officer) | Sale | 29,928 | 206.85 | 6,190,726 |
| 2022-09-21 | Oyler John (Chief Executive Officer) | Sale | 19,480 | 150.74 | 2,936,434 |
| 2022-09-20 | Oyler John (Chief Executive Officer) | Sale | 30,520 | 153.97 | 4,699,011 |
| 2022-08-08 | Wang Xiaodong | Sale | 6,060 | 202.11 | 1,224,804 |
| 2022-08-05 | Wang Xiaodong | Sale | 10,000 | 193.35 | 1,933,470 |
| 2022-07-01 | Wang Julia Aijun (Chief Financial Officer) | Sale | 295 | 158.50 | 46,757 |
| 2022-06-27 | Wang Lai (Global Head of R&D) | Sale | 458 | 177.32 | 81,214 |
| 2022-06-21 | Wang Lai (Global Head of R&D) | Sale | 723 | 149.01 | 107,733 |
| 2022-06-21 | Wu Xiaobin (President, COO & GM China) | Sale | 1,010 | 144.36 | 145,803 |
| 2022-06-17 | Wang Julia Aijun (Chief Financial Officer) | Sale | 161 | 136.64 | 21,998 |
| 2022-06-17 | Wang Lai (Global Head of R&D) | Sale | 445 | 139.40 | 62,033 |
| 2022-06-17 | Wu Xiaobin (President, COO & GM China) | Sale | 578 | 139.60 | 80,691 |
| 2022-06-06 | Wang Lai (Global Head of R&D) | Sale | 660 | 142.00 | 93,717 |
| 2022-06-06 | Wu Xiaobin (President, COO & GM China) | Sale | 3,410 | 142.00 | 484,202 |
| 2022-05-17 | Wang Lai (Global Head of R&D) | Option Ex | 1,233,947 | 2.89 | 3,566,106 |
| 2022-05-05 | Wu Xiaobin (President, COO & GM China) | Sale | 6,725 | 165.70 | 1,114,325 |
| 2021-12-14 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 279.11 | 418,662 |
| 2021-12-14 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 119.96 | 179,940 |
| 2021-12-01 | Huang Jane (CMO, Hematology) | Sale | 1,049 | 359.89 | 377,520 |
| 2021-11-17 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 381.37 | 572,052 |
| 2021-11-17 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 119.96 | 179,940 |
| 2021-11-09 | Wu Xiaobin (President, COO & GM China) | Sale | 2,334 | 368.03 | 858,977 |
| 2021-11-08 | Wu Xiaobin (President, COO & GM China) | Sale | 7,666 | 351.79 | 2,696,814 |
| 2021-11-08 | Wang Xiaodong | Sale | 9,000 | 350.79 | 3,157,141 |
| 2021-10-19 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 372.39 | 558,586 |
| 2021-10-19 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 119.96 | 179,940 |
| 2021-09-20 | Huang Jane (CMO, Hematology) | Sale | 6,000 | 399.96 | 2,399,760 |
| 2021-09-20 | Huang Jane (CMO, Hematology) | Option Ex | 6,000 | 119.96 | 719,760 |
| 2021-09-15 | Oyler John (Chief Executive Officer) | Sale | 216,361 | 339.76 | 73,510,596 |
| 2021-09-14 | Oyler John (Chief Executive Officer) | Sale | 195,477 | 332.51 | 64,999,034 |
| 2021-09-13 | Huang Jane (CMO, Hematology) | Sale | 12,901 | 359.46 | 4,637,432 |
| 2021-09-10 | Amgen Inc (10% Owner) | Buy | 165,529 | 302.06 | 50,000,020 |
| 2021-09-02 | Huang Jane (CMO, Hematology) | Sale | 545 | 327.18 | 178,313 |
| 2021-09-02 | Oyler John (Chief Executive Officer) | Sale | 24,499 | 328.65 | 8,051,669 |
| 2021-09-01 | Huang Jane (CMO, Hematology) | Sale | 542 | 310.53 | 168,307 |
| 2021-09-01 | Oyler John (Chief Executive Officer) | Sale | 153,059 | 225.50 | 34,514,345 |
| 2021-08-31 | Oyler John (Chief Executive Officer) | Sale | 111,081 | 275.69 | 30,623,809 |
Insider trading activities including stock purchases, stock sales, and option exercises of ONC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Beone Medicines Ltd. (symbol ONC, CIK number 1651308) see the Securities and Exchange Commission (SEC) website.